Treatment of klebsiella pneumoniae with liposomally formulated glutathione

{
  "publication_number": "US9421238B2",
  "country": "US",
  "kind": "B2",
  "title": "Treatment of klebsiella pneumoniae with liposomally formulated glutathione",
  "abstract": "The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.",
  "claims": [
    "1. A method of treating a Klebsiella pneumoniae infection in a mammalian patient comprising: orally administering liposomally formulated reduced glutathione, said liposomally formulated reduced glutathione being formulated from at least one phospholipid selected from the group of phosphatidylethanolamine or phosphatidylserine, wherein the reduced glutathione included inside the liposome is in an amount of at least 3.3% w/w.",
    "2. A method of treating a Klebsiella pneumoniae infection in a mammalian patient comprising: orally administering liposomally formulated reduced glutathione, said liposomally formulated reduced glutathione being formulated from lecithin, wherein the reduced glutathione included inside the liposome is in an amount of at least 3.3% w/w.",
    "3. A method of treating a Klebsiella pneumoniae infection in a mammalian patient comprising: orally administering liposomally formulated reduced glutathione, said liposomally formulated reduced glutathione being formulated from at least one ceramide, wherein the reduced glutathione included inside the liposome is in an amount of at least 3.3% w/w.",
    "4. A method of treating a Klebsiella pneumoniae infection in a mammalian patient comprising: orally administering liposomally formulated reduced glutathione, said liposomally formulated reduced glutathione being formulated from at least one cardiolipin, wherein the reduced glutathione included inside the liposome is in an amount of at least 3.3% w/w."
  ],
  "cpc": [
    "A61K 38/063",
    "A61K 9/0014",
    "A61K 9/0019",
    "A61K 9/0053",
    "A61K 9/006",
    "A61K 9/0095",
    "A61K 9/127",
    "A61K 9/4858",
    "A61P 31/04"
  ],
  "assignees": [
    "UNIV EMORY",
    "YOUR ENERGY SYSTEMS LLC",
    "CHILDREN'S HEALTHCARE OF ATLANTA INC",
    "CHILDREN'S HALTHCARE OF ATLANTA INC"
  ],
  "filing_date": "2014-02-14",
  "publication_date": "2016-08-23",
  "grant_date": "2016-08-23",
  "priority_date": "2013-02-15",
  "application_number": "US-201414767985-A",
  "family_id": "51351345",
  "citations": [
    "US2006099244A1",
    "US2010069309A1",
    "US5569464A",
    "US5843473A"
  ]
}